ITI-333 explained

Drug Name:	ITI-333
Width:	200px
C:	22
H:	24
F:	1
N:	3
O:	1
Iupac Name:	(6bR,10aS)-8-[3-(4-fluorophenoxy)propyl]-6b,7,8,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-2(3H)-one
Pubchem:	130277831
Smiles:	C1CN(C[C@@H]2[C@H]1N3CC(=O)NC4=CC=CC2=C43)CCCOC5=CC=C(C=C5)F
Stdinchi:	1S/C22H24FN3O2/c23-15-5-7-16(8-6-15)28-12-2-10-25-11-9-20-18(13-25)17-3-1-4-19-22(17)26(20)14-21(27)24-19/h1,3-8,18,20H,2,9-14H2,(H,24,27)/t18-,20-/m0/s1
Stdinchikey:	MXIJXDUPULMKIE-ICSRJNTNSA-N

ITI-333 is a drug which has a mixed mechanism of action, acting as an antagonist at the 5-HT_2A, D₁ and α1A receptors, and also as a partial agonist at the μ-opioid receptor.^[1] In animal studies it blocked the head-twitch response produced by DOI and also reduced responses to morphine, while also reducing the symptoms produced by naloxone-precipitated withdrawal in opioid habituated mice. It has been developed for potential uses in treatment of opioid withdrawal and opioid use disorder.^{[2] [3]}

See also

• IHCH-7086
• IHCH-7079
• IHCH-7113
• Lumateperone

Notes and References

1. Web site: ITI 333 . AdisInsight . 16 April 2024 . 23 October 2024.
2. Li P, Zhang Q, Zheng H, Qiao Y, Snyder GL, Martin T, Yao W, Zhang L, Davis RE . Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders . Journal of Medicinal Chemistry . 67 . 11 . 9355–9373 . June 2024 . 38805667 . 10.1021/acs.jmedchem.4c00480 . 11181336 .
3. Snyder GL, Li P, Martin T, Zhang L, Yao W, Zheng H, Maguire DR, Gerak LR, Vanover KE, France CP, Davis R . Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders . Psychopharmacology . 241 . 7 . 1477–1490 . July 2024 . 38710856 . 10.1007/s00213-024-06578-w . 11199232 .